Clinical Trials
15 trialsNCT00861705 2025-09-30
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT00295893 2025-09-25
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT03018080 2023-08-04
PePPy
Wake Forest University Health Sciences
Phase 2 Completed
NCT01147016 2023-04-27
Targeted T Cells After Neoadjuvant Chemotherapy in Treating Women With Stage II or III Breast Cancer Undergoing Surgery
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT00436566 2022-08-05
Doxorubicin and Cyclophosphamide Followed By Trastuzumab, Paclitaxel, and Lapatinib in Treating Patients With Early-Stage HER2-Positive Breast Cancer That Has Been Removed By Surgery
Mayo Clinic
Phase 2 Completed
NCT00622466 2020-10-19
Sorafenib and Paclitaxel in Treating Patients With Metastatic Breast Cancer
University of Texas Southwestern Medical Center
Phase 2 Terminated
NCT00513695 2019-08-07
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
University of Washington
Phase 2 Completed
NCT00499525 2019-05-03
Phase 2b Study of Taxol Plus Sorafenib or Placebo in Patients With Advanced Breast Cancer
Northwestern University
Phase 2 Unknown
NCT00482391 2017-05-12
Doxorubicin and Cyclophosphamide Followed by Paclitaxel, Trastuzumab, and Lapatinib in Treating Patients With HER2/Neu-Overexpressed Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00930930 2015-05-07
Cisplatin and Paclitaxel With or Without Everolimus in Treating Patients With Stage II or Stage III Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Completed
NCT00119262 2014-05-15
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00003253 2013-12-19
Evaluation of Drug Resistance in Patients With Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00007904 2012-10-02
Adjuvant Stage 2-3A Breast Cancer With Positive Lymph Nodes
Case Comprehensive Cancer Center
Phase 2 Completed
NCT00019812 2012-03-23
Monoclonal Antibody Plus Chemotherapy in Treating Patients With Metastatic Breast Cancer That Overexpresses HER2
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00002679 2009-08-26
Adjuvant High-Dose, Sequential Chemotherapy in Treating Patients With Resected Breast Cancer
Yale University
Phase 2 Completed